ClinicalTrials.gg
Not yet recruitingNCT07848295Updated Sep 30, 2026

A Study to Assess the Safety and Tolerability of BMS-986527 in Participants With Clear Cell Renal Cell Carcinoma (ccRCC)

A Phase 1 interventional study of BMS-986527 and Nivolumab in Clear Cell Renal Cell Carcinoma (ccRCC), sponsored by Juno Therapeutics, Inc., a Bristol-Myers Squibb Company. Not yet recruiting at 17 sites in 7 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-30.

Sponsored by Juno Therapeutics, Inc., a Bristol-Myers Squibb Company (part of Bristol-Myers Squibb) · Phase 1, Interventional, and Treatment

Updated Sep 30, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
112
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 42 studies in Carcinoma, Renal Cell by Bristol-Myers Squibb — 5 open to participants now, 8 under way, 2 of them phase 3. Carcinoma, Renal Cell · Bristol-Myers Squibb.

Planned enrollment
18th of 33
112 · median 119
Started
2026
with 3 others
Phase 1
13 of 42
3 open now
Registered
41st of 42
by date

Among the 42 studies in Carcinoma, Renal Cell by Bristol-Myers Squibb, this one is the 18th largest by planned enrollment of the 33 interventional ones that give a count, is one of 4 that started in 2026, is one of 13 in phase 1, and was the 41st registered.

Carcinoma, Renal Cell

2,043 studies on the registry are indexed under Carcinoma, Renal Cell; 397 are open to participants now.

Browse Carcinoma, Renal Cell studies →

Open to participants now

5 of the 42 studies in Carcinoma, Renal Cell by Bristol-Myers Squibb are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Who these studies take

Of the 309 Carcinoma, Renal Cell studies recruiting now, 256 (83%) set no upper age limit and 18 (6%) stop at 75 or younger; 21 take children under 18; 20 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 42 studies in Carcinoma, Renal Cell by Bristol-Myers Squibb, or all of them as a file.
02

Study summary

The purpose of this study is to assess the safety and tolerability of BMS-986527 in participants with Clear Cell Renal Cell Carcinoma (ccRCC)

03

Conditions studied

  • Clear Cell Renal Cell Carcinoma (ccRCC)
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants must have a confirmed diagnosis of a locally advanced and unresectable or renal cell carcinoma (RCC) with clear cell component.
  • Participants must have an (ECOG) performance status of 0 or 1.
  • Participants must have as assessed by the Investigator using version 1.1 (RECIST v1.1).
  • For Cohorts 1 and 2, participants should have previously received, be to, ineligible for, or intolerant of standard of care (SoC) immunotherapy (IO) and/or tyrosine kinase inhibitors (TKIs). Participants in Cohort 3 should have previously received, be refractory to, ineligible for, or intolerant of SoC IO, but those who have not been previously exposed to SoC TKI agents are permitted.

Exclusion criteria

Exclusion Criteria

  • Participants must not have prior history of (other than clear cell renal cell carcinoma (ccRCC)) or lymphoproliferative disease, unless the participant has been free of the disease for ≥ 2 years.
  • For Cohort 2 only: has or is refractory within 12 months of the most recent IO therapy.
  • For Cohort 3 only: use of strong inhibitor and inducers of , and P-glycoprotein (P-gp) substrates within 14 days or 5 half-lives (whichever is longer) of start of TKI.
  • Other protocol-defined Inclusion/Exclusion criteria apply.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
112 participants (estimated)

Study arms

  • Experimental
    Cohort 1: BMS-986527 monotherapy

    Drug: BMS-986527

  • Experimental
    Cohort 2: BMS-986527 with Nivolumab

    Drug: BMS-986527 · Drug: Nivolumab

  • Experimental
    Cohort 3: BMS-986527 with Cabozantinib

    Drug: BMS-986527 · Drug: Cabozantinib

Interventions

  • DrugBMS-986527

    Specified dose on specified days

  • Specified dose on specified days

    Also known as: Opdivo

  • Specified dose on specified days

    Also known as: CABOMETYX

06

What researchers measure

Primary outcomes

  1. Incidence of adverse events (AEs)

    Time frame: Up to 2 years

  2. Incidence of serious adverse events (SAEs)

    Time frame: Up to 2 years

  3. Incidence of AEs meeting protocol-defined dose-limiting toxicity (DLT) criteria

    Time frame: Up to 2 years

  4. Incidence of AEs leading to discontinuation

    Time frame: Up to 2 years

  5. Number of deaths

    Time frame: Up to 2 years

Secondary outcomes

  1. Overall response rate (ORR)

    Time frame: Up to 2 years

  2. Complete response rate (CRR)

    Time frame: Up to 2 years

  3. Disease control rate (DCR)

    Time frame: Up to 2 years

  4. Duration of response (DOR)

    Time frame: Up to 2 years

  5. Progression-free survival (PFS)

    Time frame: Up to 2 years

  6. Time to response (TTR)per investigator assessed Response Evaluation Criteria in Solid Tumors (RECIST) v1.1, or death due to any cause, whichever comes first

    Time frame: Up to 2 years

  7. Overall survival (OS)

    Time frame: Up to 2 years

  8. Maximum observed concentration (Cmax)

    Time frame: Up to 2 years

  9. Time of maximum observed concentration (Tmax)

    Time frame: Up to 2 years

  10. Area under the concentration-time curve from time zero to day 28 (AUC(0-28))

    Time frame: Up to 2 years

  11. The persistence of BMS-986527 in peripheral blood from pre-dose to post-treatment follow-up

    Time frame: Up to 2 years

07

Study locations

17 sites
  • Local Institution - 0018
    New Haven, Connecticut 06510, United States
    • Site 0018 · Contact
  • Local Institution - 0022
    Basking Ridge, New Jersey 07920, United States
    • Site 0022 · Contact
  • Local Institution - 0024
    New York, New York 10027, United States
    • Site 0024 · Contact
  • Local Institution - 0017
    Cleveland, Ohio 44195, United States
    • Site 0017 · Contact
  • Local Institution - 0019
    Houston, Texas 77030, United States
    • Site 0019 · Contact
  • Local Institution - 0026
    Seattle, Washington 98109-1024, United States
    • Site 0026 · Contact
  • Local Institution - 0004
    Ghent, Oost-Vlaanderen 9000, Belgium
    • Site 0004 · Contact
  • Local Institution - 0003
    Leuven, 3000, Belgium
    • Site 0003 · Contact
  • Local Institution - 0007
    Villejuif, Val-de-Marne 94800, France
    • Site 0007 · Contact
  • Local Institution - 0014
    Marseille, 13273, France
    • Site 0014 · Contact
  • Local Institution - 0005
    Essen, North Rhine-Westphalia 45122, Germany
    • Site 0005 · Contact
  • Local Institution - 0012
    Jena, Thuringia 07747, Germany
    • Site 0012 · Contact
  • Local Institution - 0010
    Rozzano, Milano 20089, Italy
    • Site 0010 · Contact
  • Local Institution - 0011
    Roma, 00168, Italy
    • Site 0011 · Contact
  • Local Institution - 0008
    Amsterdam, 1066 CX, Netherlands
    • Site 0008 · Contact
  • Local Institution - 0020
    Madrid, 28040, Spain
    • Site 0020 · Contact
  • Local Institution - 0002
    Madrid, 28041, Spain
    • Site 0002 · Contact
08

References and documents

Individual participant data

Plan to share: Yes — BMS will provide access to individual anonymized participant data upon request from qualified researchers, and subject to certain criteria. Additional information regarding Bristol Myer Squibb's data sharing policy and process can be found at https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: See Plan Description

Access criteria: See Plan Description

Data sharing details ↗ · www.bms.com

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Dec 2026; primary completion for Oct 2030, 45 months later.

Of 138 industry-sponsored phase 1 interventional studies under Carcinoma, Renal Cell, half reached primary completion within 49 months of starting (the median), counting those still running; a quarter within 32 and three quarters within 63. This study's planned 45 months is close to that.

Counting every sponsor, half of 220 studies reached it within 50 months; a quarter within 32 and three quarters within 73.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 22, 2026
First posted
Sep 30, 2026
StartEst.
Dec 31, 2026
Primary completionEst.
Oct 18, 2030
CompletionEst.
Apr 17, 2031
Last update
Sep 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Sep 30, 2026
Show all 1 update
  1. Sep 30, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07848295
Responsible party
Sponsor
First posted
Sep 30, 2026
Start date
Dec 31, 2026 (estimated)
Primary completion
Oct 18, 2030 (estimated)
Completion
Apr 17, 2031 (estimated)
Last update
Sep 30, 2026

Study contacts

BMS Clinical Trials Contact Center www.BMSClinicalTrials.com
Contact
Clinical.Trials@bms.com
855-907-3286
First line of the email MUST contain NCT # and Site #.
Contact
Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion